Q&A: Jeffrey Shapiro Talks Device Approval Strategy And More

The seasoned regulatory attorney, who recently moved to law firm King & Spalding, spoke to Medtech Insight about his priorities, what keeps him interested in device law, and the three things manufacturers should consider when seeking a device approval.

Keyboard, notebook, scales of justice and a gavel sit on a black background.
• Source: Shutterstock

Leading device attorney Jeffrey Shapiro has spent more than 25 years representing large, small and in-between manufacturers in their dealings with the US Food and Drug Administration. A graduate of Brown University and Harvard Law School, his areas of focus include regulatory strategy, postmarket compliance, and regulation of combination products. He’s also spoken and written on a wide range of topics from digital health to advertising.

Recently, Shapiro moved from law firm Hyman, Phelps & McNamara – where he had been a director since 2007 – to a new role as partner in the government matters...

More from Archive

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.